Proteomics International LaboratoriesLtd
Proteomics International Labs Secures US Patent for PromarkerEndo Blood Test
Proteomics International wins US patent for PromarkerEndo endometriosis blood test, boosting licensing/partnering prospects and extending protection to 2041.
Proteomics International Obtains Canadian Patent for PromarkerEso Blood Test
Proteomics International Laboratories (ASX: PIQ) has secured new intellectual property protection in Canada, after the country’s Patent Office granted a patent for its PromarkerEso blood test for esophageal adenocarcinoma.
Proteomics International Confirms US Reimbursement Price for ProMarkerD Diabetic Kidney Disease Test
Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.
Proteomics International Gains ISO 15189 Certification for Precision Diagnostics Operations
Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]